Research theme for competitive and other funds (2)：
2011 - 現在 Urology
2020 - 2022 Exploration of new therapeutic strategy targeting amino acid transporter in renal cell carcinoma
Papers (51)：
Hayato Nishida, Satoshi Takai, Hiromi Ito, Hiroki Fukuhara, Takaaki Nawano, Takafumi Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, et al. Anti-human leukocyte antigen and anti-ABO antibodies after SARS-CoV-2 mRNA vaccination in kidney transplant recipients. Clinical transplantation. 2023. e14952
Satoshi Takai, Hayato Nishida, Hiromi Ito, Hiroki Fukuhara, Takaaki Nawano, Takafumi Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, et al. Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximab. International journal of urology : official journal of the Japanese Urological Association. 2022. 29. 11. 1279-1286
Hiroki Fukuhara, Hayato Nishida, Takaaki Nawano, Satoshi Takai, Takafui Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, Sei Naito, et al. Changes in Visceral and Subcutaneous Adipose Tissue and Body Composition in Kidney Transplant Recipients at 1, 3, and 5 Years After Kidney Transplant. Transplantation Proceedings. 2022. 54. 2. 351-354
Hayato Nishida, Takaaki Nawano, Hiroki Fukuhara, Satoshi Takai, Takafumi Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, Sei Naito, et al. Outcomes of Living Kidney Transplantation for Mitochondrial Disease Patients: A Case Series. Transplantation Proceedings. 2022. 54. 2. 267-271
Satoshi Takai, Hayato Nishida, Hiromi Ito, Hiroki Fukuhara, Takaaki Nawano, Takafumi Narisawa, Hidenori Kanno, Mayu Yagi, Atsushi Yamagishi, Toshihiko Sakurai, et al. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients. Frontiers in immunology. 2022. 13. 1050211-1050211
